View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsOxford Cannabinoid Technologies Holdings 過去の業績過去 基準チェック /06Oxford Cannabinoid Technologies Holdings は平均年間 23.6% の収益成長を遂げていますが、Pharmaceuticals 業界では年間 収益成長率 となっています。12.2% です。主要情報23.57%収益成長率23.58%EPS成長率Pharmaceuticals 業界の成長5.95%収益成長率n/a株主資本利益率-217.39%ネット・マージンn/a前回の決算情報31 Oct 2023最近の業績更新お知らせ • Jan 23Oxford Cannabinoid Technologies Holdings Plc to Report First Half, 2024 Results on Jan 30, 2024Oxford Cannabinoid Technologies Holdings Plc announced that they will report first half, 2024 results on Jan 30, 2024お知らせ • Aug 22Oxford Cannabinoid Technologies Holdings Plc to Report Fiscal Year 2023 Results on Aug 31, 2023Oxford Cannabinoid Technologies Holdings Plc announced that they will report fiscal year 2023 results on Aug 31, 2023すべての更新を表示Recent updatesお知らせ • May 09Oxford Cannabinoid Technologies Intends Cancellation of Listing of its Ordinary Shares on the Standard Segment of the FCA's Official ListThe Board of Oxford Cannabinoid Technologies Holdings plc announced that it has applied to the Financial Conduct Authority ("FCA") and London Stock Exchange plc ("LSE") to effect a cancellation of listing of its ordinary shares on the Standard segment of the FCA's Official List (the "Standard List") and trading on the Main Market for listed securities of the LSE ("Main Market") ("Cancellation"). As a Standard Listed company, OCT is not required to obtain the approval of shareholders for the Cancellation. Pursuant to Listing Rule 5.2.8R, the Company is required to give at least 20 business days' notice of the intended cancellation of its listing. It is therefore anticipated that the Cancellation will become effective at 8.00am on 6 June 2024. Following the Cancellation, the Company will no longer be subject to the regulatory and statutory regime which applies to companies admitted to the Standard segment of the Official List and traded on the Main Market.お知らせ • Feb 29+ 1 more updateOxford Cannabinoid Technologies Holdings plc Announces Board Changes, Effective 31 March 2024Oxford Cannabinoid Technologies Holdings plc announced the following Board changes. Bishrut Mukherjee, Non-Executive Director, has notified the board of his intention to step down from his role in order to focus on other business interests. Bishrut has served the Company for over five years, since joining OCT in January 2019. Richard Hathaway, Non-Executive Director, has also notified the board of his intention to step down from his role in order to be able to devote more time to his other duties and responsibilities as Corporate Development Director at Imperial Brands plc ("Imperial"). Richard joined the board of OCT in February 2022 as a representative of Imperial Brands Ventures Limited, a wholly owned subsidiary of Imperial. Imperial remains a significant and supportive shareholder of the Company and Richard will continue in his role as shareholder liaison. Bishrut and Richard will leave the Company on 31 March 2024.お知らせ • Feb 15Oxford Cannabinoid Technologies Holdings Plc has completed a Follow-on Equity Offering in the amount of £0.64 million.Oxford Cannabinoid Technologies Holdings Plc has completed a Follow-on Equity Offering in the amount of £0.64 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 128,000,000 Price\Range: £0.005 Transaction Features: Subsequent Direct Listingお知らせ • Jan 23Oxford Cannabinoid Technologies Holdings Plc to Report First Half, 2024 Results on Jan 30, 2024Oxford Cannabinoid Technologies Holdings Plc announced that they will report first half, 2024 results on Jan 30, 2024お知らせ • Jan 10Oxford Cannabinoid Technologies Holdings plc Files A European Application in Own Name, Directed to Programme 2Oxford Cannabinoid Technologies Holdings plc announced that it has filed a European application in its own name, directed to Programme 2. This programme initially targets Trigeminal Neuralgia ("TN"), and the patent application filed by the Company is directed to a composition containing Delta-9-tetrahydrocannabinol and Cannabidiol. The Company intends to file an international ("PCT") patent application based on this European application within the next year. Once the patent is granted, OCTP will benefit from exclusive rights to the use, production, and sale of the composition claimed in the patent, typically for a period of up to 20 years from the filing date. This protection potentially allows OCTP to recoup its investment in R&D and secure a competitive market advantage. Patent application examination times can vary, but grant of the patent can typically be expected in 2 to 5 years from the filing date of the patent application. The precise timing will depend on the examination process at the patent office and any objections or oppositions that may arise. The Company expects to file several other patent applications directed to other aspects of Programme 2 during 2024.お知らせ • Nov 15Oxford Cannabinoid Technologies Holdings plc Appoints Tim Corn as an Executive DirectorOxford Cannabinoid Technologies Holdings plc announced the following Board appointment. The Company announced the appointment of Dr. Tim Corn, Chief Medical Officer (CMO), as an executive director, effective immediately. As announced on 8 June 2023, Dr. Corn joined OCTP as CMO to oversee the Company's clinical research and development activities as well as to provide expert medical guidance and advice to the team. Since joining, the Company has successfully completed its first Phase I clinical trial, a single ascending dose study of its lead compound OCT461201. Dr. Corn, formerly Chief Medical Officer International at Jazz Pharmaceuticals plc, has played a key role in the successful conclusion of more than twenty regulatory approvals in the US and Europe and is the author of more than forty scientific publications. He was elected Fellow of both the Faculty of Pharmaceutical Medicine and the Royal College of Psychiatrists.お知らせ • Oct 10Oxford Cannabinoid Technologies Holdings plc Announces Phase I Clinical Trial Results for Lead Drug Candidate OCT461201Oxford Cannabinoid Technologies Holdings plc announced that dosing of all the cohorts of the Phase I, single ascending dose study for OCT461201 has been successfully completed. No safety or tolerability concerns were exhibited with any dose tested. As a result, OCTP is satisfied that it is safe to proceed to the next stage of clinical development of its lead compound OCT461201. The trial was conducted in the UK in healthy volunteers by Simbec Research Limited, part of Simbec-Orion Group Ltd, using a single ascending dose protocol. The final dose was administered on 20 September 2023, followed by formal review of final clinical data on 2 October 2023. The trial's primary objective was to demonstrate the safety and tolerability of OCT461201, whilst also providing important information on its pharmacokinetic profile.お知らせ • Sep 25Oxford Cannabinoid Technologies Holdings plc Announces Final Dose Administered in Phase I Clinical TrialOxford Cannabinoid Technologies Holdings plc announced that the final dose of its lead pharmaceutical drug compound, OCT461201, has been successfully administered, as part of its Phase I clinical trial, with no drug adverse effects observed. The trial is being conducted in the UK in healthy volunteers by Simbec Research Limited, part of Simbec-Orion Group Ltd, using a single ascending dose protocol. The final dose was successfully administered on 20 September 2023, in line with the Company's previously announced timeframe. The trial's principal objective is to demonstrate the safety and tolerability of OCT461201, whilst also providing pivotal information on its pharmacokinetic profile, to confirm its value as a potential drug. The Company expects to report results by 16 October 2023.お知らせ • Sep 01Oxford Cannabinoid Technologies Holdings Plc, Annual General Meeting, Sep 28, 2023Oxford Cannabinoid Technologies Holdings Plc, Annual General Meeting, Sep 28, 2023, at 10:00 Coordinated Universal Time. Location: Penningtons Manches Cooper LLP at 125 Wood Street, London London United Kingdomお知らせ • Aug 22Oxford Cannabinoid Technologies Holdings Plc to Report Fiscal Year 2023 Results on Aug 31, 2023Oxford Cannabinoid Technologies Holdings Plc announced that they will report fiscal year 2023 results on Aug 31, 2023お知らせ • Jul 18Oxford Cannabinoid Technologies Holdings plc Announces Expansion into Oncology Potential New Cannabinoid-Based Treatment of Cancer MalignanciesOxford Cannabinoid Technologies Holdings plc is formally expanding its research and development strategy into oncology having identified a potential "first in class" immunotherapy agent for the treatment of solid tumours. The Company's analysis of the initial data shows excellent drug-like potential in terms of in vitro potency and selectivity to target, as well as in vivo availability in blood. This implies substantive potential for the development of a cannabinoid-based medicine that could be taken at home, as a tablet. The asset has arisen from the work being carried out on OCTP's cannabinoid library of almost 500 derivatives for the Company's Programme 4 and further demonstrates the value in OCTP's exclusive licence agreement with Canopy Growth Corporation. At this early stage of development, management believes the potency shown on the selected target in vitro, in addition to its in vivo behaviour, demonstrates significant potential. attention will now focus on further in vitro and in vivo studies to highlight the full potential of this lead-cand candidate. This will be followed by a safety-pharmacology assessment before final candidate selection, likely during 2024. This work will be carried out using the existing cash resources of the Company. The OCTP team has discovered a potential first-line-treatment alternative to existing therapies and their side effects which could provide a viable alternative to expensive biologics. Although the company're at an early stage, this is exciting news for the Company. As the potential of cannabinoid-based medicines to treat a range of conditions in a less harmful and more economic manner receives growing public recognition, OCTP stands at the forefront of research & development and company are extremely excited to have identified a possible candidate that could have a significant impact on many people' lives.お知らせ • Jun 09Oxford Cannabinoid Technologies Holdings plc Announces Appointment of Tim Corn as Chief Medical OfficerOxford Cannabinoid Technologies Holdings plc announced the appointment of Dr. Tim Corn as the Company's new Chief Medical Officer effective immediately. Dr. Corn is an independent pharmaceuticals consultant who has held senior positions in both large and small pharma organisations. He is currently CMO at Nodenza Inc. and Medical Adviser to Confo Therapeutics SA, which recently announced a global licensing deal with Eli Lilly and Company for the clinical stage peripheral pain candidate CFTX-1554 and back-up compounds. He also serves as a non-executive director on the Board of Physiomics plc. He was formerly Chief Medical Officer International at Jazz Pharmaceuticals plc and CMO at venture-backed companies EUSA Pharma Inc, acquired by Jazz Pharmaceuticals plc in 2012, and Zeneus Pharma Ltd, acquired by Cephalon Inc. in 2005. Dr Corn has also played a key role in the successful conclusion of more than twenty regulatory approvals in the US and Europe and is the author of more than forty scientific publications. He was elected a Fellow of both the Faculty of Pharmaceutical Medicine and the Royal College of Psychiatrists. Dr. Corn will oversee the Company's clinical research and development activities as well as providing expert medical guidance and advice to the team.お知らせ • May 19Oxford Cannabinoid Technologies Holdings plc Announces Mhra and Rec 2 Approval of Phase I Clinical Trial ApplicationOxford Cannabinoid Technologies Holdings Plc announced that the Medicines and Healthcare Products Regulatory Agency ("MHRA") and the Wales Research Ethics Committee 2 ("REC 2") have approved the Company's combined Phase I clinical trial application for OCTP's lead drug candidate, OCT461201. This Phase I first-in-human clinical trial is being conducted in the UK in healthy volunteers, with a single ascending dose protocol. The trial is being conducted by Simbec Research Limited, part of Simbec-Orion Group Ltd. ("Simbec-Orion") and aims to demonstrate the safety and tolerability of OCT461201, whilst also providing pivotal information on its pharmacokinetic profile, to confirm its value as a potential drug. Participants enrolment will begin immediately, and the trial is expected to be completed during Third Quarter 2023. The trial is being funded entirely from OCTP's existing resources. Growing global opportunity OCT461201 is a selective cannabinoid receptor type 2 agonist which has shown potential as an effective therapy for chemotherapy induced peripheral neuropathy ("CIPN") as well as irritable bowel syndrome ("IBS"). The global market for CIPN alone is currently valued at USD 1.61 billion and is forecast to reach USD 2.37 billion by 2027.お知らせ • Jan 16Oxford Cannabinoid Technologies Holdings plc Announces Appointment of General Counsel and Company SecretaryOxford Cannabinoid Technologies Holdings plc, for approval by global regulatory agencies and targeting the USD multi-billion pain market, announced the appointment of Robin ("Rob") Bennett as General Counsel and Company Secretary. Rob joined the Company in December 2022 as General Counsel and was appointed Company Secretary on 12 January 2023. Rob brings a wealth of experience and expertise to the Company from his role as General Counsel and Company Secretary at Bestway Wholesale (formerly Costcutter Supermarkets Group). He has over 15 years of UK and international experience across multiple sectors, including retail, fast-moving consumer goods, manufacturing, innovation and FinTech. His knowledge in legal, risk and compliance has been gained through working with SMEs and quoted companies such as SABMiller plc. He has been recognised for his work by being listed in Legal 500's GC Powerlists in 2021 and 2022 and as a Team of the Year finalist at The Lawyer Awards in 2021.お知らせ • Jan 06Oxford Cannabinoid Technologies Holdings plc Submits Combined Clinical Trials Application for Its Lead Programme, OCT461201Oxford Cannabinoid Technologies Holdings plc announced that on 4 January 2023 it submitted a combined clinical trials application for its lead programme, OCT461201, to the UK Medicines & Healthcare products Regulatory Agency (MHRA) and Wales Research Ethics Committee (REC) 2 (the Submission) in preparation for a review meeting to be held on 11 January 2023. The Submission follows the successful completion of OCTP's extensive pre-clinical work on OCT461201, under the Group's £2.6 million contract research agreement with Aptuit (Verona) SRL, a subsidiary of Evotec SE. OCT461201 is a selective cannabinoid receptor type 2 agonist which has shown potential as an effective therapy for chemotherapy induced peripheral neuropathy ("CIPN") as well as irritable bowel syndrome ("IBS"). The global market for CIPN alone was valued at USD 1.61 billion in 2020 and is forecast to reach USD 2.37 billion by the year 2027. This Phase I first-in-human clinical trial, due to commence in first quarter 2023, which is being funded entirely from OCTP's existing resources, will be conducted in the UK in healthy volunteers, with a single ascending dose. The trial aims to demonstrate the safety and tolerability of OCT461201, whilst also providing pivotal information on its pharmacokinetic profile, to confirm its value as a potential drug. The clinical trial is anticipated to complete within second quarter 2023.収支内訳Oxford Cannabinoid Technologies Holdings の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:OCTH.F 収益、費用、利益 ( )GBP Millions日付収益収益G+A経費研究開発費31 Oct 230-43031 Jul 230-53030 Apr 230-63030 Apr 220-530質の高い収益: OCTH.Fは現在利益が出ていません。利益率の向上: OCTH.Fは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: OCTH.Fの過去 5 年間の前年比収益成長率がプラスであったかどうかを判断するにはデータが不十分です。成長の加速: OCTH.Fの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: OCTH.Fは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( 1% ) と比較することは困難です。株主資本利益率高いROE: OCTH.Fは現在利益が出ていないため、自己資本利益率 ( -217.39% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/08/05 12:41終値2024/05/08 00:00収益2023/10/31年間収益2023/04/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Oxford Cannabinoid Technologies Holdings Plc 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Soo RomanoffEdison Investment Research
お知らせ • Jan 23Oxford Cannabinoid Technologies Holdings Plc to Report First Half, 2024 Results on Jan 30, 2024Oxford Cannabinoid Technologies Holdings Plc announced that they will report first half, 2024 results on Jan 30, 2024
お知らせ • Aug 22Oxford Cannabinoid Technologies Holdings Plc to Report Fiscal Year 2023 Results on Aug 31, 2023Oxford Cannabinoid Technologies Holdings Plc announced that they will report fiscal year 2023 results on Aug 31, 2023
お知らせ • May 09Oxford Cannabinoid Technologies Intends Cancellation of Listing of its Ordinary Shares on the Standard Segment of the FCA's Official ListThe Board of Oxford Cannabinoid Technologies Holdings plc announced that it has applied to the Financial Conduct Authority ("FCA") and London Stock Exchange plc ("LSE") to effect a cancellation of listing of its ordinary shares on the Standard segment of the FCA's Official List (the "Standard List") and trading on the Main Market for listed securities of the LSE ("Main Market") ("Cancellation"). As a Standard Listed company, OCT is not required to obtain the approval of shareholders for the Cancellation. Pursuant to Listing Rule 5.2.8R, the Company is required to give at least 20 business days' notice of the intended cancellation of its listing. It is therefore anticipated that the Cancellation will become effective at 8.00am on 6 June 2024. Following the Cancellation, the Company will no longer be subject to the regulatory and statutory regime which applies to companies admitted to the Standard segment of the Official List and traded on the Main Market.
お知らせ • Feb 29+ 1 more updateOxford Cannabinoid Technologies Holdings plc Announces Board Changes, Effective 31 March 2024Oxford Cannabinoid Technologies Holdings plc announced the following Board changes. Bishrut Mukherjee, Non-Executive Director, has notified the board of his intention to step down from his role in order to focus on other business interests. Bishrut has served the Company for over five years, since joining OCT in January 2019. Richard Hathaway, Non-Executive Director, has also notified the board of his intention to step down from his role in order to be able to devote more time to his other duties and responsibilities as Corporate Development Director at Imperial Brands plc ("Imperial"). Richard joined the board of OCT in February 2022 as a representative of Imperial Brands Ventures Limited, a wholly owned subsidiary of Imperial. Imperial remains a significant and supportive shareholder of the Company and Richard will continue in his role as shareholder liaison. Bishrut and Richard will leave the Company on 31 March 2024.
お知らせ • Feb 15Oxford Cannabinoid Technologies Holdings Plc has completed a Follow-on Equity Offering in the amount of £0.64 million.Oxford Cannabinoid Technologies Holdings Plc has completed a Follow-on Equity Offering in the amount of £0.64 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 128,000,000 Price\Range: £0.005 Transaction Features: Subsequent Direct Listing
お知らせ • Jan 23Oxford Cannabinoid Technologies Holdings Plc to Report First Half, 2024 Results on Jan 30, 2024Oxford Cannabinoid Technologies Holdings Plc announced that they will report first half, 2024 results on Jan 30, 2024
お知らせ • Jan 10Oxford Cannabinoid Technologies Holdings plc Files A European Application in Own Name, Directed to Programme 2Oxford Cannabinoid Technologies Holdings plc announced that it has filed a European application in its own name, directed to Programme 2. This programme initially targets Trigeminal Neuralgia ("TN"), and the patent application filed by the Company is directed to a composition containing Delta-9-tetrahydrocannabinol and Cannabidiol. The Company intends to file an international ("PCT") patent application based on this European application within the next year. Once the patent is granted, OCTP will benefit from exclusive rights to the use, production, and sale of the composition claimed in the patent, typically for a period of up to 20 years from the filing date. This protection potentially allows OCTP to recoup its investment in R&D and secure a competitive market advantage. Patent application examination times can vary, but grant of the patent can typically be expected in 2 to 5 years from the filing date of the patent application. The precise timing will depend on the examination process at the patent office and any objections or oppositions that may arise. The Company expects to file several other patent applications directed to other aspects of Programme 2 during 2024.
お知らせ • Nov 15Oxford Cannabinoid Technologies Holdings plc Appoints Tim Corn as an Executive DirectorOxford Cannabinoid Technologies Holdings plc announced the following Board appointment. The Company announced the appointment of Dr. Tim Corn, Chief Medical Officer (CMO), as an executive director, effective immediately. As announced on 8 June 2023, Dr. Corn joined OCTP as CMO to oversee the Company's clinical research and development activities as well as to provide expert medical guidance and advice to the team. Since joining, the Company has successfully completed its first Phase I clinical trial, a single ascending dose study of its lead compound OCT461201. Dr. Corn, formerly Chief Medical Officer International at Jazz Pharmaceuticals plc, has played a key role in the successful conclusion of more than twenty regulatory approvals in the US and Europe and is the author of more than forty scientific publications. He was elected Fellow of both the Faculty of Pharmaceutical Medicine and the Royal College of Psychiatrists.
お知らせ • Oct 10Oxford Cannabinoid Technologies Holdings plc Announces Phase I Clinical Trial Results for Lead Drug Candidate OCT461201Oxford Cannabinoid Technologies Holdings plc announced that dosing of all the cohorts of the Phase I, single ascending dose study for OCT461201 has been successfully completed. No safety or tolerability concerns were exhibited with any dose tested. As a result, OCTP is satisfied that it is safe to proceed to the next stage of clinical development of its lead compound OCT461201. The trial was conducted in the UK in healthy volunteers by Simbec Research Limited, part of Simbec-Orion Group Ltd, using a single ascending dose protocol. The final dose was administered on 20 September 2023, followed by formal review of final clinical data on 2 October 2023. The trial's primary objective was to demonstrate the safety and tolerability of OCT461201, whilst also providing important information on its pharmacokinetic profile.
お知らせ • Sep 25Oxford Cannabinoid Technologies Holdings plc Announces Final Dose Administered in Phase I Clinical TrialOxford Cannabinoid Technologies Holdings plc announced that the final dose of its lead pharmaceutical drug compound, OCT461201, has been successfully administered, as part of its Phase I clinical trial, with no drug adverse effects observed. The trial is being conducted in the UK in healthy volunteers by Simbec Research Limited, part of Simbec-Orion Group Ltd, using a single ascending dose protocol. The final dose was successfully administered on 20 September 2023, in line with the Company's previously announced timeframe. The trial's principal objective is to demonstrate the safety and tolerability of OCT461201, whilst also providing pivotal information on its pharmacokinetic profile, to confirm its value as a potential drug. The Company expects to report results by 16 October 2023.
お知らせ • Sep 01Oxford Cannabinoid Technologies Holdings Plc, Annual General Meeting, Sep 28, 2023Oxford Cannabinoid Technologies Holdings Plc, Annual General Meeting, Sep 28, 2023, at 10:00 Coordinated Universal Time. Location: Penningtons Manches Cooper LLP at 125 Wood Street, London London United Kingdom
お知らせ • Aug 22Oxford Cannabinoid Technologies Holdings Plc to Report Fiscal Year 2023 Results on Aug 31, 2023Oxford Cannabinoid Technologies Holdings Plc announced that they will report fiscal year 2023 results on Aug 31, 2023
お知らせ • Jul 18Oxford Cannabinoid Technologies Holdings plc Announces Expansion into Oncology Potential New Cannabinoid-Based Treatment of Cancer MalignanciesOxford Cannabinoid Technologies Holdings plc is formally expanding its research and development strategy into oncology having identified a potential "first in class" immunotherapy agent for the treatment of solid tumours. The Company's analysis of the initial data shows excellent drug-like potential in terms of in vitro potency and selectivity to target, as well as in vivo availability in blood. This implies substantive potential for the development of a cannabinoid-based medicine that could be taken at home, as a tablet. The asset has arisen from the work being carried out on OCTP's cannabinoid library of almost 500 derivatives for the Company's Programme 4 and further demonstrates the value in OCTP's exclusive licence agreement with Canopy Growth Corporation. At this early stage of development, management believes the potency shown on the selected target in vitro, in addition to its in vivo behaviour, demonstrates significant potential. attention will now focus on further in vitro and in vivo studies to highlight the full potential of this lead-cand candidate. This will be followed by a safety-pharmacology assessment before final candidate selection, likely during 2024. This work will be carried out using the existing cash resources of the Company. The OCTP team has discovered a potential first-line-treatment alternative to existing therapies and their side effects which could provide a viable alternative to expensive biologics. Although the company're at an early stage, this is exciting news for the Company. As the potential of cannabinoid-based medicines to treat a range of conditions in a less harmful and more economic manner receives growing public recognition, OCTP stands at the forefront of research & development and company are extremely excited to have identified a possible candidate that could have a significant impact on many people' lives.
お知らせ • Jun 09Oxford Cannabinoid Technologies Holdings plc Announces Appointment of Tim Corn as Chief Medical OfficerOxford Cannabinoid Technologies Holdings plc announced the appointment of Dr. Tim Corn as the Company's new Chief Medical Officer effective immediately. Dr. Corn is an independent pharmaceuticals consultant who has held senior positions in both large and small pharma organisations. He is currently CMO at Nodenza Inc. and Medical Adviser to Confo Therapeutics SA, which recently announced a global licensing deal with Eli Lilly and Company for the clinical stage peripheral pain candidate CFTX-1554 and back-up compounds. He also serves as a non-executive director on the Board of Physiomics plc. He was formerly Chief Medical Officer International at Jazz Pharmaceuticals plc and CMO at venture-backed companies EUSA Pharma Inc, acquired by Jazz Pharmaceuticals plc in 2012, and Zeneus Pharma Ltd, acquired by Cephalon Inc. in 2005. Dr Corn has also played a key role in the successful conclusion of more than twenty regulatory approvals in the US and Europe and is the author of more than forty scientific publications. He was elected a Fellow of both the Faculty of Pharmaceutical Medicine and the Royal College of Psychiatrists. Dr. Corn will oversee the Company's clinical research and development activities as well as providing expert medical guidance and advice to the team.
お知らせ • May 19Oxford Cannabinoid Technologies Holdings plc Announces Mhra and Rec 2 Approval of Phase I Clinical Trial ApplicationOxford Cannabinoid Technologies Holdings Plc announced that the Medicines and Healthcare Products Regulatory Agency ("MHRA") and the Wales Research Ethics Committee 2 ("REC 2") have approved the Company's combined Phase I clinical trial application for OCTP's lead drug candidate, OCT461201. This Phase I first-in-human clinical trial is being conducted in the UK in healthy volunteers, with a single ascending dose protocol. The trial is being conducted by Simbec Research Limited, part of Simbec-Orion Group Ltd. ("Simbec-Orion") and aims to demonstrate the safety and tolerability of OCT461201, whilst also providing pivotal information on its pharmacokinetic profile, to confirm its value as a potential drug. Participants enrolment will begin immediately, and the trial is expected to be completed during Third Quarter 2023. The trial is being funded entirely from OCTP's existing resources. Growing global opportunity OCT461201 is a selective cannabinoid receptor type 2 agonist which has shown potential as an effective therapy for chemotherapy induced peripheral neuropathy ("CIPN") as well as irritable bowel syndrome ("IBS"). The global market for CIPN alone is currently valued at USD 1.61 billion and is forecast to reach USD 2.37 billion by 2027.
お知らせ • Jan 16Oxford Cannabinoid Technologies Holdings plc Announces Appointment of General Counsel and Company SecretaryOxford Cannabinoid Technologies Holdings plc, for approval by global regulatory agencies and targeting the USD multi-billion pain market, announced the appointment of Robin ("Rob") Bennett as General Counsel and Company Secretary. Rob joined the Company in December 2022 as General Counsel and was appointed Company Secretary on 12 January 2023. Rob brings a wealth of experience and expertise to the Company from his role as General Counsel and Company Secretary at Bestway Wholesale (formerly Costcutter Supermarkets Group). He has over 15 years of UK and international experience across multiple sectors, including retail, fast-moving consumer goods, manufacturing, innovation and FinTech. His knowledge in legal, risk and compliance has been gained through working with SMEs and quoted companies such as SABMiller plc. He has been recognised for his work by being listed in Legal 500's GC Powerlists in 2021 and 2022 and as a Team of the Year finalist at The Lawyer Awards in 2021.
お知らせ • Jan 06Oxford Cannabinoid Technologies Holdings plc Submits Combined Clinical Trials Application for Its Lead Programme, OCT461201Oxford Cannabinoid Technologies Holdings plc announced that on 4 January 2023 it submitted a combined clinical trials application for its lead programme, OCT461201, to the UK Medicines & Healthcare products Regulatory Agency (MHRA) and Wales Research Ethics Committee (REC) 2 (the Submission) in preparation for a review meeting to be held on 11 January 2023. The Submission follows the successful completion of OCTP's extensive pre-clinical work on OCT461201, under the Group's £2.6 million contract research agreement with Aptuit (Verona) SRL, a subsidiary of Evotec SE. OCT461201 is a selective cannabinoid receptor type 2 agonist which has shown potential as an effective therapy for chemotherapy induced peripheral neuropathy ("CIPN") as well as irritable bowel syndrome ("IBS"). The global market for CIPN alone was valued at USD 1.61 billion in 2020 and is forecast to reach USD 2.37 billion by the year 2027. This Phase I first-in-human clinical trial, due to commence in first quarter 2023, which is being funded entirely from OCTP's existing resources, will be conducted in the UK in healthy volunteers, with a single ascending dose. The trial aims to demonstrate the safety and tolerability of OCT461201, whilst also providing pivotal information on its pharmacokinetic profile, to confirm its value as a potential drug. The clinical trial is anticipated to complete within second quarter 2023.